Objective: To assess the importance of plasma semicarbazide-sensitive amine oxidase (SSAO) as a diagnostic tool in chronic heart failure (CHF) with left ventricular systolic dysfunction.
P-362 DIFFERENT EFFICACY OF AMLODIPINE VS CANDESARTAN ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE TYPE 2 DIABETIC PATIENTS
The aim of the study is to evaluate the efficacy of amlodipine in comparison with candesartan in hypertensive diabetic patients with left ventricular hypertrophy (LVH).
A total of 64 mild to moderate hypertensive non albuminuric type 2 diabetic patients with LVH (LVMIϾ 131 g/m2 in men and Ͼ100 g/m2 in women) after a 4 week placebo period were enrolled in a 12 month randomized, double blind parallel group study to compare the effects of candesartan ( 8 mg o.d.) with amlodipine ( 5 mg o.d.): after 2 months of treatment the patients non responders ( DBP Ն 90 mmHg) were given a double dose of each drug; the patients yet non responders at the 3rd month were given additional treatment with hydrochlorothiazide 12.5 mg. The patients non responders at the 4th month of treatment were discontinued. A total of 27 candesartan and 29 amlodipine treated patients completed the study. Echocardiographic evaluation was performed at the end of the placebo period and after 1 year of active treatment.
Patients of both groups were similar with regard the duration of diabetes, hypertension, SBP and DBP at rest, degree of LVH and metabolic control. Both drugs were equally effective in reducing BP ( amlodipine: from 162Ϯ12/101Ϯ6 to 143Ϯ10/86Ϯ5 mmHg; candesartan from 161Ϯ11/100Ϯ6 to 146Ϯ9/88Ϯ5 mmHg) but not in reversing LVH because it decreased significantly more in the amlodipine group as compared with the candesartan group ( 19.7Ϯ3 vs 10.8Ϯ5 g/m2 respectively, 8.9[0.14-21] g/m2 mean difference [95% CI]; pϭ 0.039).
Our results show that in hypertensive type 2 diabetic patients amlodipine induces a regression of LVH greater than candesartan independent of reduction in systemic blood pressure. It suggests that in this type of patients the Angiotensin II antagonism is less important than the calcium channel blockade for reversing LVH.
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P-363 LOW DOSES OF PERINDOPRIL AND INDAPAMIDE CONTROL LEFT VENTRICULAR MASS IN OBESE ZUCKER RATS (fa/fa)

Jorge E. Toblli, Ana Uceda, Pedro Forcada, Carlos Rivas. Lab. Exp Medicine, Hospital Alemán, Buenos Aires, Argentina.
Obesity, NIDDM and hypertension are leading causes associated with increased CV morbidity and mortality. Left ventricular hypertrophy has been documented as a frequent complication of all of them. The aim of our study was to evaluate if low doses of perindopril ϩ indapamide (PTX) can control left ventricular mass (LVM) in Obese Zucker rats (OZR) (fa/fa). 10-week-old male OZR were used for this experiment. G1 (nϭ 8) OZR with vehicle and G2 (nϭ 8) OZRϩPTX with 1m/kg/day of PTX orally, at ratio of doses 0.32, for six months. At baseline and after 6 months of treatment with placebo or PTX, echocardiograms were performed with ATL HDI 3000 equipment with a 10 mHz. transducer. We evaluated: a)LV diastolic diameter (LVDD); b)LV systolic diameter (LVSD); c) Interventricular septum (IVS); d)LV posterior wall (LVPW); e)LVM; f)Fractional shortening (FS). Systolic Blood pressure (SBP) was recorded by tail cuff method. Mann-Whitney test with ␣ ϭ 0.05. Results on 6 th . month:
OZR-PTX (G2) showed a significant reduction in myocardial dimensions and a higher FS, without modification in blood sugar and with improvement in the insulin / glucose ratio, when compared with OZR untreated (G1). These results suggest that PTX can control LVM and it provides an additional help in the metabolic scenario. 
